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The increasing prevalence of diabetes mellitus is a major public health burden causing 59 significant morbidity and mortality worldwide. Twenty percent of diabetic patients develop 60 nephropathy (54); which is the leading cause of end stage renal failure in the adult population 61 (10). However the molecular pathways critically involved in the development of diabetic 62 nephropathy are still not fully understood. 63
Hexosamine biosynthesis pathway activity is increased in diabetes resulting in protein O-64 linked N-Acetylglucosamine modification (O-GlcNAcylation), which is a central contributor 65 of glucose toxicity (8, 12, 20, 37) . During the process of O-GlcNAcylation O-GlcNAc 66 transferase (OGT) adds a single O-GlcNAc moiety to serine and/or threonine residues of 67 various proteins (24, 25) ; while O-GlcNAcase (OGA) removes the modification (16, 21, 55) . 68
The two enzymes keep the rate of glycoslyation and deglycosylation in a dynamic equilibrium 69 and fine tune multiple cellular and metabolic processes in a glucose-dependent manner (37) . 70 O-GlcNAcylation is one of the most common posttranslational modifications. In some 71
proteins O-GlcNAcylation and phosphorylation competitively modify the same 72 serine/threonine residues and thus have a reciprocal effect to each other (36, 58) . This cross 73 talk with phosphorylation is especially important in endothelial nitric oxide synthase (eNOS) 74
activity. In endothelial cells hyperglycemia increased eNOS O-GlycNAcylation with an 75
inverse relation to eNOS phosphorylation (19) . The same has been observed in aortas of 76 diabetic animals where O-GlcNAc modification of eNOS was increased parallel to decreased 77 phosphorylation (7, 17) . Diabetes was induced in male Wistar rats by a single intraperitoneal injection of 107 streptozotocin (STZ) (65 mg x bwkg -1 ) dissolved in 0.1 M citrate buffer (pH 4.5). Blood 108 glucose level was measured from tale vein after an overnight fast. Animals with ≥15 mmol/L 109 blood glucose concentrations were considered to be diabetic. 110
Five weeks after the induction of diabetes rats were randomized into 4 groups 111 (n=8/group). For a period of two weeks rats received once daily either vehicle (D), or 112 Enalapril (D+Enalapril, 40 mg/bwkg/day), or Losartan (D+Losartan, 20 mg/bwkg/day), or 113 selective aldosterone antagonist Eplerenone (D+Eplerenone 50 mg/bwkg/day) by oral gavage. 114
The effective dose of each RAAS inhibitor was adopted from previous studies to avoid blood 115 pressure changes while remaining effective in blocking the components of RAAS (13, 18, 116 50) . Age-matched non-diabetic animals (n= 8/group) injected with citrate buffer, and gavaged 117 with vehicle only served as controls. 118
At the end of the protocol anaesthetized rats were sacrificed. Blood and urinary samples 119 were collected, kidneys were removed and weighted, and the cortical parts of the kidneys 120 were separated with the naked eye and were immediately snap-frozen for further 121
investigation. 122 123
In vitro model 124
Human proximal tubular cell line (HK-2) was cultured in DMEM containing 35 mM 125 glucose (Gibco, Life Technologies Corporation) and supplemented with 10% FBS 126 (Gibco, Life Technologies Corporation), 1% L-glutamine and 1% antibiotic-antimycotic 127
The cells were incubated in humidified 95% air/ 5% CO 2 at 37°C. Cells were plated 129 (5x10 5 cells/well) in 6-well plates (Sarstedt) for 24 hours in serum-free medium. Cells were 130 kept under normal (C; 5.5 mM) or high glucose (HG; 35 mM) condition either for 24 (HG24) 131 or 48 hours (HG48). HG cells were treated either with Enalapril (HG+Enalapril, 1µM), 132
Losartan (HG+Losartan, 10µM) or Eplerenone (HG+Eplerenone 10µM) (n=12 well/group, 133 500 000 cells/well). All substances were purchased from Sigma-Aldrich. Cells were detached 134 with 0.25% trypsin-EDTA (Gibco, Life Technologies Corporation) then lysed with the same 135 buffer used for the kidney homogenates. In both time points untreated and mannitol (35 mM) 136 treated cells were used as controls. 137
To determine cell viability cells were incubated with Thiazolyl-blue (MTT) for 4 h 138 followed by lysis in DMSO/ethanol (1:1). The formation of water-insoluble formazan was 139 determined by measuring optical density at 570 nm in Plate Chameleon V Fluorometer-140
Luminometer-Photom reader (Hidex, Turku, Finland Masson's trichome. To determine tubulointestitial fibrosis 10 areas of 200 x magnification, 162 without glomeruli were randomly selected from each kidney cross-section with Panoramic 163
Viewer (3DHISTECH Ltd.) and the stained interstitial area was measured. The number of 164 pixels containing blue fibrotic tissue was divided by the total number of pixels in the area to 165 obtain the percentage of tubulointerstitial fibrosis (14). Analysis was performed by a 166 nephropathologist in a double blinded fashion with computer-assisted morphometry using 167
Adobe Photoshop CS6 (Adobe Systems Corporation, USA) and Scion Image 1.49v (National 168
Institutes of Health, USA) softwares. Appropriate controls were performed omitting the primary antibody to assure specificity and 210 to avoid autofluorescence. 211
212
Statistical analysis 213
Results are presented as mean ± SEM. Statistical analysis was performed using GraphPad 214 Prism software (version 5.00; GraphPad Software, Inc., USA). Multiple comparisons and 215 possible interactions were evaluated by one-way ANOVA followed by Bonferroni's multiple 216 comparison post hoc test. For non-parametrical data the Kruskal-Wallis ANOVA on ranks 217 was used. P values < 0.05 were considered significant. HG48. Mannitol-induced hyperosmolality had no effect on HSP72 (Figure 3. D) . 264 265
Development of diabetic nephropathy in diabetic rats 266
Blood pressure, metabolic and renal parameters are summarized in Table 1 . After 7 267 weeks of diabetes rats had significant weight loss, higher blood glucose, fructosamine and 268 lipid levels reflecting to metabolic changes associated with the development of diabetes. 269
RAAS inhibitors did not influence the metabolic parameters with the exception of Losartan 270
which reduced the level of cholesterol. 271
In diabetic rats serum creatinine and BUN increased, while GFR decreased. Here we 272 confirmed our previous results (5) Increased protein O-GlcNAcylation was observed in kidney cortex homogenates of 285 diabetic rats. All RAAS-blockers decreased protein O-GlcNAcylation (Fig. 5. A-B) . We are 286 the first to detect different OGT and OGA isoforms in the kidney. Renal ncOGT and mOGT 287 were decreased in diabetic rats compared to controls, while RAAS-inhibitors had no effect on 288 OGT levels ( Figure 5. C-D) . 289
OGA-L was downregulated in the diabetic kidneys, while O-GlcNAcylation was 290
increased. In parallel OGA-S -which is found in the nucleus and is associated with lipid-291 droplets (11, 31) -was increased. Only Losartan ameliorated the reduction of OGA-L, while 292
OGA-S was decreased by all RAAS-blockers (Figure 5. E-F). 293 294
RAAS-blockers rescued decreased eNOS phosporylation in the diabetic kidney cortex 295
The level of phosphorylated eNOS, as well as peNOS/eNOS ratio were decreased in 296 diabetic rats. Treatment with RAAS inhibitors, especially with Losartan and Eplerenone 297 increased peNOS levels. Elevated total eNOS levels were mitigated by RAAS-blockers 298 (Figure 6 . A-C). However Akt was slightly elevated in diabetes, but neither pAkt nor 299 pAkt/Akt ratio were altered by RAAS-blocker treatment (Figure 6 . D-F). 300
301
HSP72 protein level is decreased in the diabetic kidney cortex 302 303 HSP72 was localized in the tubules as seen in the representative confocal images. Renal 304 HSP72 protein level was lower in diabetes, RAAS-blockers tended to increase HSP72 (Figure  305 
7.). 306 307
Discussion
309
OglcNAcylation is one of the most common, but least studied posttranslational 310 modifications. While its relevance has been emphasized in the diabetic heart, OglcNAc 311 modification has not been studied in the diabetic kidney yet. Here we showed that 312 hyperglycemia induces O-GlcNAcylation, which contributes to the progression of diabetic 313 nephropathy via the inhibition of Akt/eNOS phosphorylation and HSP72 induction. We also 314 demonstrated that RAAS-blockers could ameliorate the detrimental effects of chronic 315 accumulation of O-GlcNAc modified proteins. 316
However OGT and OGA, the isoforms of the O-GlcNAc cycling enzymes are different 317 in subcellular localization and substrate specificity (11, 26) ; only a few studies discuss the 318 effects of the two isoforms separately. Here we found that after hyperglicaemia ncOGT -319 which is responsible for O-GlcNAcylation in the nucleus and cytoplasm (39) -transiently 320 increased, but on the long-run it was down-regulated. Similarly to ncOGT, the mitochondria-321 localized mOGT which also has catalytic activity (4) decreased as well, both in tubular cells 322 and in the diabetic kidney cortex. These data suggest that in the case of chronic 323 hyperglicaemia renal OGT decreases in a compensatory manner in order to protect tubular 324 cells against over-O-GlcNAcylation. The same phenomenon was demonstrated in the red 325 blood cells of diabetic human subjects (47). 326
In contrast to OGT, OGA appears to be less sensitive to nutritive changes and more 327 susceptible to cellular O-GlcNAc levels. Here we found that after a transient decline, OGA-L 328 quickly increases in proximal tubules, which could be an adaptive response to increased O-329
GlcNAcylation. This is in line with previous studies showing that OGA level is higher in the 330 erythrocytes of pre-diabetic individuals suggesting that cells are trying to accommodate to 331 hyperglycaemia by elevating OGA already at an early state of diabetes (47). On the other 332 hand since OGA-L was here decreased in diabetic kidneys, it is also conceivable that instead 333 of a regulator, OGA is rather an O-GlcNAc-independent indicator of disease progression. All these data suggest a bilateral activation of O-GlcNAcylation and intrarenal RAAS that 350 generates a vicious circle contributing to a direct glucotoxic effect that can be inhibited by 351
RAAS-blockers. 352
Increasing evidence suggests that in contrast to chronic effects, acute elevation of O-353
GlcNAcylation stimulates pro-survival signaling pathways (9). Increased O-GlcNAc levels 354
promote the translocation of heat shock factor and the expression of HSP72 -which is a 355 prominent cytoprotective chaperon in the kidney (57). Here we found that HSP72 was 356 promptly increased after high glucose treatment in proximal tubules, but decreased after 357 chronic hyperglycaemia (in the diabetic kidneys). This suggest that heat shock response is 358 impaired in chronic hyperglycaemia resulting in diminished HSP synthesis contributing to the 359 progression of diabetic nephropathy (1, 45, 46) . 360
It became evident in the past decades that the development and/or progression of 361 diabetic nephropathy is associated with alterations in eNOS, however its importance has been 362 primarily emphasized in the renal vascular endothelium. It is also known that a bidirectional 363 link exists between HSPs and nitric oxide (NO); NO has direct effects on heat-shock factor-364 mediated HSP expression (56), while HSP70 increases eNOS (53). We are the first to 365 demonstrate that hyperglycemia inhibits eNOS phosphorylation in proximal tubular cells. In 366 parallel lower eNOS phosphorylation was detected in diabetic kidney cortex as well. Since it 367 is well known that O-GlcNAcylation interacts with protein phosphorylation (27), we presume 368 that hyperglycemia-induced elevation of O-GlcNAc plays a role in decreased phosphorylation 369 of eNOS in diabetes. 370
pAkt is a key mediator of eNOS activation via phosphorylating eNOS on Ser1177 (15). 371
It is well established that Akt is also O-GlcNAcylated, which decreases Akt phosphorylation 372 (22, 40). Therefore we hypotesize that lower Akt phosphorylation in diabetic rats could be a 373 result of increased O-GlcNAcylation. Furthermore it is also conceivable that the O-GlcNAc 374 modification of Akt inhibits phosphorylation thus the activation of eNOS. Therefore our data 375 might in a way explain the findings of various other studies showing that Akt/eNOS 376 phosphorylation is depressed in the diabetic kidney (32, 52) . 377
In summary here we highlighted the significance of increased protein O-378
GlcNAcylation in the pathomechanism of diabetic nephropathy. We showed a time-dependent 379 and isoform-specific expression pattern of O-GlcNAcylation enzymes OGT and OGA under 380 hyperglycemia. As a possible consequence of increased O-GlcNAcylation we also 381 demonstrated the impairment of Akt/eNOS signaling and HSP72 expression in diabetes. 382 
Finally we concluded that RAAS-blockers successfully ameliorate protein O-GlcNAcylation
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